Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...

The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...

A Q&A With Rajesh Gandhi, MD. GANDHI: The main reasons patients and their clinicians consider switching are to simplify treatment, reduce drug interactions, and mitigate long-term safety risks. In my ...

Three chemical structures with various rods and rings in multiple colors appear over a gray, bumpy background. An X-ray crystal structure of MK-8527 triphosphate (TP) bound to the complex of HIV ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

HIV Virus Creative artwork featuring colorized 3D prints of HIV virus particles. The virus surface (red) is covered with proteins (dark blue) that enable the virus to enter and infect human cells, and ...

Nucleoside reverse transcriptase inhibitor exposure is significantly associated with a reduced risk for subsequent development of Alzheimer disease, reinforcing the idea that inflammasome inhibition ...

Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, Key Laboratory of Chemical Biology (Ministry of Education), School of ...

On Thursday, the FDA approved lenacapavir, to be sold as Yeztugo, for the prevention of HIV in the U.S. The below essay, adapted from “Breakthrough: The Quest for Life-Changing Medicine” by William ...